Fremanezumab: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
DMC (Denmark), G-BA (Germany) and HIRA (South Korea), among others, recommended or restricted fremanezumab, while AOTMIT (Poland) did not recommend it.
Assessment has run over 6.5 years, from 18 Mar 2019 at AWMSG (Wales) to 24 Sep 2025 at PHARMAC (New Zealand).
HAS (France) changed its position: not recommended on 16 Sep 2020, recommended by 9 Apr 2025, after a resubmission.
No assessment is on file from CIPM (Spain), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for fremanezumab, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 4 of 20 records date from 2023 or later.
5 distinct indication wordings are recorded for fremanezumab by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
5 of these 20 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess fremanezumab, on 18 Mar 2019; PHARMAC (New Zealand) did not open a file until 24 Sep 2025 — a wide spread of 6.5 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 6 years in total.
Restriction is doing real work here: 4 of 15 decisive outcomes narrowed fremanezumab to a subgroup rather than accepting or refusing it outright, at DMC (Denmark), NICE (England) and SMC (Scotland) among others.
3 of the 13 agencies here assessed fremanezumab more than once, PBAC (Australia) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
fremanezumab has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for fremanezumab reads 9 recommended, 4 restricted, 2 not recommended and 1 withdrawn, with 4 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 24 Sep 2025 | Chronic migraine prevention | PTAC advice: High | source |
| PBAC (Australia) | 2024 | Treatmentresistant migraine (change to maximum quantity and number of repeats) | The PBAC rescinded the March 2022 recommendation for fremanezumab. | source |
| HIRA (South Korea) | 1 Sep 2022 | 편두통의 예방 | reimbursement appropriate | source |
| NICE (England) | 2 Feb 2022 | NICE TA764 | recommended (optimised) | source |
| HAS (France) | 16 Sep 2020 | Listing (Transparency Committee) | SMR insufficient · ASMR V | source |
15 further decisions for fremanezumab, across 11 agencies, are not shown here. They link to 9 further source documents.
Related molecules
- galcanezumab — same ATC class N02C — Analgesics
- erenumab — same ATC class N02C — Analgesics
- atogepant — same ATC class N02C — Analgesics
- rimegepant — same ATC class N02C — Analgesics
- eptinezumab — same ATC class N02C — Analgesics
- sumatriptan — same ATC class N02C — Analgesics
Coverage: 20 decisions for fremanezumab from 13 agencies, 2019 to 2025. Data to 7 Sep 2026. ATC class N02C — Analgesics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.